We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 20, 2022

Sugemalimab vs Placebo After Concurrent or Sequential Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC

The Lancet Oncology


Additional Info

The Lancet Oncology
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
Lancet Oncol 2022 Jan 14;[EPub Ahead of Print], Q Zhou, M Chen, O Jiang, Y Pan, D Hu, Q Lin, G Wu, J Cui, J Chang, Y Cheng, C Huang, A Liu, N Yang, Y Gong, C Zhu, Z Ma, J Fang, G Chen, J Zhao, A Shi, Y Lin, G Li, Y Liu, D Wang, R Wu, X Xu, J Shi, Z Liu, N Cui, J Wang, Q Wang, R Zhang, J Yang, YL Wu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading